# The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function

> **NCT06587386** · PHASE4 · COMPLETED · sponsor: **Affiliated Hospital of Jiaxing University** · enrollment: 55 (actual)

## Conditions studied

- Motion Sickness

## Interventions

- **DRUG:** First patient Bupivacaine liposome and next patient Bupivacaine liposome

## Key facts

- **NCT ID:** NCT06587386
- **Lead sponsor:** Affiliated Hospital of Jiaxing University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-20
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-11-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06587386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06587386, "The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06587386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*